None listed
Conditions
Brief summary
The objective of this study is to evaluate the bioequivalence of the test (new) formulation of 500 mg tranexamic acid tablet relative to that of the reference formulation (innovator brand of 500 mg tranexamic acid tablet) following oral administration of a single dose of 500 mg in healthy male and female subjects under fasting conditions
Interventions
Single dose, crossover over study design whereby each participant receives the test formulation of tranexamic acic (1 x 500 mg) on one occasion and the innovator formulation of tranexamic acic (1 x 500 mg) on one occasion with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of tranexamic acid.
Each dose (1 x 500 mg) will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check wil
Single dose, crossover over study design whereby each participant receives the test formulation of tranexamic acic (1 x 500 mg) on one occasion and the innovator formulation of tranexamic acic (1 x 500 mg) on one occasion with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of tranexamic acid. Each dose (1 x 500 mg) will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed. No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose). Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance can be monitored and for 13 hours after dosing. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing. Screening laboratory tests (including HIV, Hepatitis and drugs of abuse testing), and post study laboratory tests will be completed to assess the health of participants.
Sponsors
Zenith Technology Corp Ltd
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy males and Females Aged between 18 and 55 Non-smoker BMI between 18 and 33 Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests Able to provide written informed consent
Exclusion criteria
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches Concomitant drug therapy of any kind History of or family history of thromboembolic disease such as deep vein thrombosis (DVT), pulmonary embolism and cerebral thrombosis, antithrombin III deficiency or Factor V Leiden mutation. Any acquired colour vision disturbance. Pregnant or breast-feeding Sensitivity to tranexamic acid or any excipients of tranexamic acid History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug Smoker (anyone who has smoked in the last 6 months) History of alcohol or drug abuse or dependency Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study. Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk.
Outcome results
None listed